Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Leases (2019 - 2025)

Denali Therapeutics (DNLI) has disclosed Current Leases for 7 consecutive years, with $9.2 million as the latest value for Q3 2025.

  • Quarterly Current Leases rose 14.04% to $9.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9.2 million through Sep 2025, up 14.04% year-over-year, with the annual reading at $8.3 million for FY2024, 14.44% up from the prior year.
  • Current Leases for Q3 2025 was $9.2 million at Denali Therapeutics, up from $8.9 million in the prior quarter.
  • The five-year high for Current Leases was $9.2 million in Q3 2025, with the low at $4.9 million in Q1 2021.
  • Average Current Leases over 5 years is $7.0 million, with a median of $7.1 million recorded in 2022.
  • The sharpest move saw Current Leases skyrocketed 34.58% in 2022, then decreased 0.79% in 2023.
  • Over 5 years, Current Leases stood at $5.5 million in 2021, then surged by 34.2% to $7.3 million in 2022, then decreased by 0.79% to $7.3 million in 2023, then increased by 14.44% to $8.3 million in 2024, then grew by 10.3% to $9.2 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $9.2 million, $8.9 million, and $8.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.